reMYND’s ReS19-T program, managing calcium homeostasis for Alzheimer’s, has moved to MAD phase after demonstrating strong safety in SAD phase
21-10-2021

Leuven Belgium, 21 October 2021: reMYND NV, a clinical stage company, is pleased to announce that it has initiated the multiple-ascending-dose (MAD) phase of its Alzheimer’s program after observing no compound-related ReS19-T adverse events so far in the 58 healthy volunteers in the single-ascending dose (SAD) phase.

Read more
reMYND announces Clinical Advisory Board to support development of Alzheimer’s programme
19-05-2021

Leuven Belgium, 20 May 2021: reMYND NV, a clinical stage company developing innovative treatments for Alzheimer’s, diabetes and other diseases caused by cellular dysfunction, is pleased to announce the Clinical Advisory Board (CAB) which will support the Company as it progresses its programme in Alzheimer’s disease (“Alzheimer’s”).

Read more
reMYND commences first-in-human trial of ReS19-T Alzheimer’s program
02-12-2020

-  RES-19T represents a novel approach to treat Alzheimer’s at the root of the disease and restore cognition

-  Board and Senior Leadership team strengthened; appointment of Staph Leavenworth Bakali as Chair and Hermann Russ as Chief Medical Officer

 

Read more
Interreg. project "Memories" update
01-07-2020

An intermediate update on the progress of identifying differently expressed microRNA in Alzheimer's Disease.

Read more
Approved project ‘Memories’: early diagnostics of Alzheimer’s disease (AD)
08-03-2018

Interreg granted a positive ruling on the project ‘Memories’ mid-December. reMYND will team up with the consortium partners ToxGenSolutions, Icometrix, KU Leuven, Maastricht University and UAntwerpen to support AD research aimed at a sustainable, inclusive growth among Flanders and South-Netherlands. The entire project will receive almost € 800.000 in funding from Interreg. The province of Flemish Brabant will support the project with an additional sum of nearly € 150.000.

Read more
reMYND receives grants from Flanders and Europe to advance break-through treatments in Epilepsy and Alzheimer’s
14-03-2017
reMYND NV today announced that it has received two grants from Flanders and Europe to advance break-through treatments in Epilepsy and Alzheimer’s respectively.
Read more
reMYND to present on Biotechdag
19-10-2015
reMYND will be presenting on the research towards the treatment of Alheimers and diabetes worldwide.
Read more
IWT supports reMYND in developing a cure for Type 1 Diabetes
23-06-2015
reMYND announced that it has received a grant from IWT to assess the potential of its Diabetes program in curing Type 1 Diabetes Mellitus (T1DM).
Read more
reMYND’s novel diabetes treatment prevents – and even reverses – disease progression in pre-clinical diabetes models
05-05-2014
reMYND NV announced today that its experimental diabetes drug ReS39 has demonstrated a strong disease modifying effect in mice
Read more
Roche and reMYND's DDD enter into a strategic alliance to develop first-in-class disease-modifying treatments for Parkinson's and Alzheimer's disease
27-03-2014
Roche (SIX: RO, ROG; OTCQX: RHHBY) and reMYND today announced that they have entered into an agreement.
Read more